FOR INFORMATION CONTACT:
Lori Gardner, Senior Director
Communications & Marketing
301.984.9496 ext. 226
For Immediate Release: September 20, 2007
Association of Community Cancer Centers to Honor Tennessee Oncologist and Researcher David H. Johnson, MD
ROCKVILLE, Md.—David H. Johnson, MD, will be honored with the Association of Community Cancer Centers’ annual Clinical Research Award. Dr. Johnson is director, Division of Hematology/Oncology, at Vanderbilt University Medical School in Nashville, Tenn., and deputy director of the Vanderbilt-Ingram Cancer Center. He will be honored for his extensive research, leadership, and commitment to individuals with lung and breast cancers.
Dr. Johnson will receive the award at ACCC’s 24th National Oncology Economics Conference on Thursday, October 4, 2007, in Dallas, Texas. ACCC’s Clinical Research Award is given to an individual whose research has significantly and positively impacted the oncology patient, family, and community.
Dr. Johnson’s clinical research interests are focused mainly on the management of thoracic malignancies and experimental therapeutics. He is co-principal investigator of the Vanderbilt-Ingram Cancer Center’s Lung Cancer Specialized Program of Research Excellence (SPORE) grant. From 1988 through 2003, he served as chairman of the Thoracic Oncology Committee of the Eastern Cooperative Oncology Group (ECOG). Under his leadership a number of important clinical trials were undertaken within ECOG, including most recently the pivotal study that led to the FDA approval of bevacizumab (Avastin) in non-small cell lung cancer.
Dr. Johnson has served on many national committees related to patient care, education, and research: the NCI Clinical Trials Program Review Group, the National Cancer Institute (NCI) Clinical Trials Implementation Committee, the NCI Lung Cancer Progress Review Group, the NCI Clinical Oncology Study Section, the U.S. Food and Drug Administration Oncologic Drug Advisory Committee, and the American College of Physicians MKSAP-II Oncology Committee. He is the author of more than 350 peer-reviewed articles, reviews, and book chapters, and is a member of several editorial advisory boards.
Actively involved in numerous professional associations, including the American Society of Clinical Oncology (ASCO), he served as ASCO president, 2004-2005. He is a member of the board of directors at the International Association for the Study of Lung Cancer and the National Comprehensive Cancer Network (NCCN). Dr. Johnson has been listed as one of the “top doctors” in the nation in America’s Top Doctors rankings.